Orforglipron Guide
The Oral GLP-1 Pill With No Injection and No Fasting
Orforglipron is Eli Lilly's oral non-peptide GLP-1 agonist — no injection required, no fasting window before dosing. The Phase 3 ATTAIN trial demonstrated 14.7% mean weight loss at 36 weeks. This guide covers the mechanism, dosing schedule, side-effect profile, and expected FDA approval timeline.
What Is Orforglipron?
Orforglipron (LY3502970) is Eli Lilly's investigational oral GLP-1 receptor agonist. Unlike every other GLP-1 medication on the market, it's a non-peptide small molecule—meaning it doesn't need special formulation to survive the digestive system.
Why this matters: Current oral GLP-1 (Rybelsus) requires strict fasting and timing because the semaglutide peptide is fragile. Orforglipron's small molecule structure is more robust, allowing it to be taken with food at any time.
Administration: Once-daily oral pill, taken with or without food. No fasting, no timing restrictions, no injections.
Orforglipron vs Rybelsus
Key advantage: Rybelsus's strict requirements cause poor adherence. Orforglipron's flexibility could dramatically improve real-world effectiveness.
Key Biohacking Mechanics
Clinical Trial Results
Who Will Benefit Most?
Expected Dosing
Side Effects
Development Timeline
Why This Changes Everything
Vital Protocol FAQs
Guide FAQs
Complete guide to Orforglipron - Eli Lilly
Yes. Shotlee supports tracking Orforglipron doses, side effects, and health metrics. It is free to use.
Track Your Orforglipron Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.